{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:17Z","timestamp":1786977857562,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Europe, pembrolizumab with or without chemotherapy is the recommended first\u2010line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC), with a combined positive score (CPS) \u2265\u20091. In France, the TPExtreme (TPEx) regimen is preferred for CPS &lt;\u20091. These regimens were studied in selected populations, which may not reflect real\u2010world patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed all R\/M HNSCC cases treated with first\u2010line regimens between January 2021 and December 2023 in Nancy and Lille. Data on patient history, treatments, survival, response, and safety were collected. PFS and OS were analyzed using the Cox multivariable regression model, adjusting for the covariates age, Eastern Cooperative Oncology Group (ECOG) performance status, comorbidities, and nutritional status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 290 patients; 19% received pembrolizumab alone, 28% received pembrolizumab with chemotherapy, 19% received TPEx, and 20% received adapted regimens. PFS and OS differed significantly between groups. Median PFS and OS were respectively 2.9 and 9.4\u2009months for pembrolizumab, 6 and 15.5\u2009months for pembrolizumab\u2010chemotherapy, 5.9 and 13.7\u2009months for TPEx, and 4.3 and 10\u2009months for adapted regimens. Pembrolizumab alone is the safest regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective study reflects real\u2010world first\u2010line therapy for R\/M HNSCC in two French cancer institutes. Pembrolizumab combined with chemotherapy is the preferred treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hed.28211","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T03:05:30Z","timestamp":1749524730000},"page":"2939-2949","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["First\u2010Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real\u2010World Study"],"prefix":"10.1002","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6321-2465","authenticated-orcid":false,"given":"Aliz\u00e9e","family":"Simon","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Institut de Canc\u00e9rologie de Lorraine  Nancy France"},{"name":"Facult\u00e9 de m\u00e9decine de Nancy Universit\u00e9 de Lorraine  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Abdeddaim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Centre Oscar Lambret  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DucTrung","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of ENT \u2010 Head and Neck Surgery Centre Hospitalier Regional Universitaire de Nancy  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Gallet","sequence":"additional","affiliation":[{"name":"Department of ENT \u2010 Head and Neck Surgery Centre Hospitalier Regional Universitaire de Nancy  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Peiffert","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Institut de Canc\u00e9rologie de Lorraine  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Institut de Canc\u00e9rologie de Lorraine  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionnel","family":"Geoffrois","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Institut de Canc\u00e9rologie de Lorraine  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-3284-2-22"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30755-5"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.09.113"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01031-z"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003410"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113110"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.775"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00332"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00136-4"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051180"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6014"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13071326"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005158"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.28211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:25:57Z","timestamp":1761125157000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.28211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/hed.28211"],"URL":"https:\/\/doi.org\/10.1002\/hed.28211","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}